Neurodegenerative Diseases  >>  AADvac1  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AADvac1 / Axon Neurosci
NCT01850238: Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease

Completed
1
30
Europe
AADvac1, (no commercial or INN name assigned yet), Placebo, (no other names)
Axon Neuroscience SE
Alzheimer Disease
03/15
03/15
FUNDAMANT, NCT02031198: 18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease

Completed
1
25
Europe
AADvac1, Axon peptide 108 (coupled to KLH), 40ug/0.3mL, Axon peptide 108 conjugated to KLH
Axon Neuroscience SE
Alzheimer's Disease
08/16
12/16

Download Options